Impact of second forward-view examination on adenoma detection rate during unsedated colonoscopy: a randomized controlled trial.

Adenoma detection rate Colonic polyps Colonoscopy Colorectal cancer Polyp detection rate Second forward-view examination

Journal

BMC gastroenterology
ISSN: 1471-230X
Titre abrégé: BMC Gastroenterol
Pays: England
ID NLM: 100968547

Informations de publication

Date de publication:
10 May 2021
Historique:
received: 05 01 2021
accepted: 19 04 2021
entrez: 11 5 2021
pubmed: 12 5 2021
medline: 13 5 2021
Statut: epublish

Résumé

Colorectal cancer on the right side of the colon has been suggested to be harder to detect by colonoscopy. The aim of this study was to evaluate whether a second forward-view examination of the right side of the colon could increase the adenoma detection rate (ADR) and/or polyp detection rate (PDR). This was a single-centre randomized controlled trial. Patients undergoing colonoscopy were recruited and randomly assigned to the second forward-view examination (SFE) group, in which the right side of the colon was examined twice or the traditional colonoscopy (TC) group in which the colonoscopy was performed in a standard manner. The primary outcome was the ADR of right colon. The overall PDR and ADR, PDR of the right colon, per-adenoma miss rate of the right colon, and advanced lesion detection rate were also recorded and compared. A total of 392 patients were included in the study (SFE group 197 vs. TC group 195). The ADR and PDR of the right colon in the SFE group were significantly higher than those in the TC group (ADR 10.7% vs. 5.1%; P = 0.042); PDR 17.8% vs. 9.7%, P = 0.021). No significant difference was found in overall PDR/ADR, or advanced lesion detection rate between the two groups. This prospective controlled study revealed that a second forward-view examination could modestly increase the ADR and PDR of the right colon during unsedated colonoscopies. This simple, safe and time-effective technique might be recommended for routine unsedated colonoscopy. Clinical Trials.gov, NCT03619122. Registered on 7/8/2018.

Identifiants

pubmed: 33971824
doi: 10.1186/s12876-021-01783-9
pii: 10.1186/s12876-021-01783-9
pmc: PMC8111781
doi:

Banques de données

ClinicalTrials.gov
['NCT03619122']

Types de publication

Journal Article Randomized Controlled Trial

Langues

eng

Sous-ensembles de citation

IM

Pagination

213

Références

Gastrointest Endosc. 2019 Mar;89(3):453-459.e3
pubmed: 30222971
Dis Colon Rectum. 2008 Aug;51(8):1217-20
pubmed: 18500502
Gastrointest Endosc. 2015 Mar;81(3):608-13
pubmed: 25440687
Gastrointest Endosc. 2011 Mar;73(3):480-9
pubmed: 21067735
Gut. 2017 Apr;66(4):683-691
pubmed: 26818619
J Interv Gastroenterol. 2011 Jan;1(1):19-22
pubmed: 21686108
N Engl J Med. 2012 Feb 23;366(8):687-96
pubmed: 22356322
Gut Liver. 2012 Jan;6(1):64-70
pubmed: 22375173
Am J Gastroenterol. 2010 Mar;105(3):663-73; quiz 674
pubmed: 19904239
Am J Gastroenterol. 2012 Dec;107(12):1837-48
pubmed: 23147522
Am J Gastroenterol. 2015 Mar;110(3):415-22
pubmed: 25732415
Gastroenterology. 2009 Mar;136(3):832-41
pubmed: 19171141
Gastroenterology. 2015 Oct;149(4):952-7
pubmed: 26164494
CA Cancer J Clin. 2019 Jan;69(1):7-34
pubmed: 30620402
Gastrointest Endosc. 2011 Aug;74(2):246-52
pubmed: 21679946
Gastrointest Endosc. 2016 Jul;84(1):126-32
pubmed: 26769408
Histopathology. 2013 Feb;62(3):367-86
pubmed: 23339363
Endoscopy. 2017 Mar;49(3):243-250
pubmed: 28129661
Intest Res. 2015 Oct;13(4):326-31
pubmed: 26576138
J Natl Cancer Inst. 2010 Jan 20;102(2):89-95
pubmed: 20042716
Am J Gastroenterol. 2016 Feb;111(2):197-204; quiz 205
pubmed: 26782820
Digestion. 2016;93(3):234-47
pubmed: 27119347
Dis Colon Rectum. 2014 Jan;57(1):110-4
pubmed: 24316954
Endoscopy. 2012 May;44(5):470-5
pubmed: 22441756
J Clin Gastroenterol. 2017 Oct;51(9):818-824
pubmed: 27683963
Am J Gastroenterol. 2006 Dec;101(12):2866-77
pubmed: 17227527
Cancer. 2012 Jun 15;118(12):3044-52
pubmed: 21989586
J Natl Med Assoc. 2018 Apr;110(2):143-148
pubmed: 29580447
N Engl J Med. 2006 Dec 14;355(24):2533-41
pubmed: 17167136

Auteurs

Keshu Shan (K)

China Department of Gastroenterology, Ningbo First Hospital, 59 Liuting St, Ningbo, 315010, Zhejiang, China.

Hongpeng Lu (H)

China Department of Gastroenterology, Ningbo First Hospital, 59 Liuting St, Ningbo, 315010, Zhejiang, China.

Zhixin Zhang (Z)

College of Medicine, Ningbo University, Ningbo, 315010, Zhejiang, China.

Jiarong Xie (J)

College of Medicine, Ningbo University, Ningbo, 315010, Zhejiang, China.

Lu Xu (L)

College of Medicine, Ningbo University, Ningbo, 315010, Zhejiang, China.

Weihong Wang (W)

China Department of Gastroenterology, Ningbo First Hospital, 59 Liuting St, Ningbo, 315010, Zhejiang, China.

Chunjiu Hu (C)

China Department of Gastroenterology, Ningbo First Hospital, 59 Liuting St, Ningbo, 315010, Zhejiang, China.

Lei Xu (L)

China Department of Gastroenterology, Ningbo First Hospital, 59 Liuting St, Ningbo, 315010, Zhejiang, China. xulei22@163.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH